Heidi Raises $340M for AI Healthcare Expansion

Australian healthtech innovator, Heidi, has successfully closed a significant funding round totaling $340 million, propelling its ambitious expansion of artificial intelligence solutions across global healthcare systems. The substantial capital injection, comprising a $100 million Series C led by Blackbird and a $240 million growth investment from General Catalyst’s Customer Value Fund, positions the company for a new phase of development and market penetration. This funding underscores the increasing investor confidence in AI's transformative potential within the complex healthcare sector.

The Series C round saw participation from existing backers including Phoenix Court, Point72 Private Investments, and Headline, signaling continued support for Heidi's vision. The additional $240 million growth capital is earmarked to accelerate Heidi's market reach and facilitate deeper integration within major healthcare organizations. This strategic infusion will bolster efforts in product enhancement, clinical research, and navigating regulatory pathways as the company broadens its AI capabilities beyond initial clinical documentation support.

Heidi's platform is already demonstrating considerable scale, currently supporting an estimated 2.8 million patient visits weekly across 190 countries and accommodating 110 languages. Since its inception just two years ago, the company's technology has facilitated over 175 million patient visits and accumulated more than 67 million clinical hours. This rapid growth is further evidenced by a dramatic increase in annual recurring revenue, which surged from $1 million to $50 million within approximately two years, reaching the latter milestone in April 2026.

Initially gaining traction with AI-powered software for clinical note generation, Heidi is now evolving its strategy to develop a comprehensive 'AI Care Partner.' This advanced solution aims to assist physicians and other healthcare professionals throughout their entire workday, moving beyond mere documentation to actively support clinical workflows. The company is focusing on AI tools that can manage administrative tasks, retrieve pertinent patient information, and prepare findings for clinician review, all while maintaining physician oversight of critical decisions.

The company's impact is already being felt in major healthcare institutions worldwide. In the United States, Beth Israel Lahey Health utilizes Heidi's technology. Notably, NHS England Midlands selected Heidi as its exclusive AI supplier, a procurement described as the largest clinical AI deal in NHS history. Further deployments include prominent Australian hospitals such as The Royal Children’s Hospital Melbourne, Children’s Health Queensland Hospital and Health Service, and Metro South Health, alongside every emergency department in New Zealand.

Heidi's commitment to innovation extends to its product portfolio. The Heidi Evidence platform, launched in March 2026, provides context-aware clinical guidelines at the point of care, having already addressed over 10 million queries. The introduction of Remote, a wearable device for audio capture in diverse healthcare settings, and the Dictate feature for direct voice-to-text input, further illustrate the company's expanding offerings. These advancements are supported by proprietary clinical AI technology, allowing for tailored accuracy, speed, and cost management, distinct from general-purpose models. A portion of the new funding will be dedicated to generating clinical evidence, enhancing quality management, and pursuing regulatory approvals for its advanced agentic capabilities.